Local radiation therapy appears beneficial for men with bone metastatic hormone-sensitive prostate cancer (mHSPC).
Bayer seeks European approval for darolutamide in combo with ADT in patients with metastatic hormone-sensitive prostate cancer: Berlin Wednesday, October 16, 2024, 13:00 Hrs [IST] ...
Bayer is seeking EMA approval for darolutamide in metastatic hormone-sensitive prostate cancer, building on promising Phase ...
A guideline panel indirectly studied cardiotoxicity among advanced prostate cancer treatments (mHSPC, mCRPC, CRPC).
Medpage Today on MSN3d
Radioligand Shows Promise in Metastatic Hormone-Sensitive Prostate CancerIn metastatic hormone-sensitive prostate cancer (mHSPC), adding the radioligand 177 Lu-PSMA-617 (Pluvicto) to androgen ...
DelveInsight's 'Metastatic Castration-Sensitive Prostate Cancer Pipeline Insight 2024' report provides comprehensive global ...
ORION CORPORATION INVESTOR NEWS 14 OCTOBER 2024 at 11.00 EEST Orion’s collaboration partner Bayer submits application for third indication of darolutamide in the EU Orion’s collaboration partner Bayer ...
BAYRY submits an application seeking EMA approval of elinzanetant for treating hot flashes associated with menopause or ...
In this feature we spoke to Michael J. Morris, MD, and Benjamin Garmezy, MD, on the future of radioligand therapy in patients ...
3,4 Overall, data from the trial showed that darolutamide plus ADT significantly extended radiological progression-free survival (rPFS) compared with placebo plus ADT in patients with mHSPC. At 24 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback